7.3 Epilepsy & Movement Disorders (Parkinson's Disease)
Key Takeaways
- Seizures are classified as focal onset or generalized onset; broad-spectrum anti-seizure medications (levetiracetam, lamotrigine, valproate, topiramate) treat both types, whereas narrow-spectrum agents (carbamazepine, oxcarbazepine, phenytoin) are reserved for focal seizures and may worsen generalized absence/myoclonic seizures.
- Carbamazepine displays auto-induction (therapeutic range 4–12 mcg/mL) and mandates HLA-B*1502 screening in Asian descent to avoid fatal SJS/TEN; phenytoin exhibits Michaelis-Menten non-linear kinetics (therapeutic range 10–20 mcg/mL total, 1–2 mcg/mL free) requiring Sheiner-Tozer correction in hypoalbuminemia.
- Topiramate causes cognitive slowing ('Dopamax'), nephrolithiasis, oligohidrosis (reduced sweating/hyperthermia), and weight loss via carbonic anhydrase inhibition; lacosamide requires baseline ECG monitoring due to PR interval prolongation.
- Parkinson's disease cardinal motor features follow the TRAP mnemonic (Tremor, Rigidity, Akinesia/bradykinesia, Postural instability); carbidopa/levodopa is the gold standard requiring ≥70–100 mg/day of carbidopa to saturate peripheral DOPA decarboxylase and prevent severe peripheral nausea.
- PD motor fluctuations are managed strategically: 'wearing-off' is addressed with COMT inhibitors (entacapone) or MAO-B inhibitors (rasagiline), while peak-dose dyskinesia is treated with levodopa dose reduction or amantadine; pimavanserin treats PD psychosis without worsening motor deficits.
Epilepsy & Movement Disorders (Parkinson's Disease)
Executive Summary: Epilepsy and Parkinson's Disease (PD) are complex, progressive neurological disorders managed extensively in the ambulatory setting. For the Board Certified Ambulatory Care Pharmacist (BCACP), clinical mastery demands applying the International League Against Epilepsy (ILAE) classification to select broad-spectrum vs. narrow-spectrum Anti-Seizure Medications (ASMs), mastering complex non-linear pharmacokinetics (phenytoin Michaelis-Menten kinetics, Sheiner-Tozer corrections) and pharmacogenomics (HLA-B*1502 with carbamazepine), optimizing carbidopa/levodopa regimens under strict peripheral decarboxylase saturation thresholds (≥70–100 mg carbidopa daily), resolving motor fluctuations ('wearing-off' vs. peak-dose dyskinesias), and avoiding high-risk Beers criteria medications in older adults.
1. ILAE Seizure Classification & Broad-Spectrum Anti-Seizure Medications (ASMs)
The International League Against Epilepsy (ILAE 2017) categorizes seizures based on onset:
- Focal Onset: Originates within neuronal networks limited to one cerebral hemisphere. Subdivided into Focal Aware (consciousness preserved) and Focal Impaired Awareness (consciousness altered/lost); can progress to bilateral tonic-clonic.
- Generalized Onset: Originates at some point within and rapidly engages bilaterally distributed networks. Subdivided into Motor (generalized tonic-clonic, atonic, myoclonic) and Non-Motor (absence seizures).
+---------------------------------------------------------------------------------------+
| BROAD-SPECTRUM VS. NARROW-SPECTRUM ASM SPECTRUM |
+------------------------------------+--------------------------------------------------+
| ASM Category & Definition | Specific Medications in Category |
+------------------------------------+--------------------------------------------------+
| **Broad-Spectrum ASMs** | **Levetiracetam, Lamotrigine, Valproic Acid, |
| (Effective for Focal AND | Topiramate, Zonisamide, Brivaracetam, Clobazam** |
| Generalized seizures including | *(Safe initial choice when seizure type is |
| absence and myoclonic)** | unclassified or ambiguous)* |
+------------------------------------+--------------------------------------------------+
| **Narrow-Spectrum ASMs** | **Carbamazepine, Oxcarbazepine, Phenytoin, |
| (Effective ONLY for Focal seizures;| Lacosamide, Gabapentin, Pregabalin, Vigabatrin** |
| **MAY EXACERBATE** absence or | *(Avoid in primary generalized epilepsy; can |
| myoclonic seizures)** | trigger absence status or myoclonic storms)* |
+------------------------------------+--------------------------------------------------+
Broad-Spectrum ASM Clinical Pearls
- Levetiracetam (Keppra: 500–1500 mg BID):
- Mechanism: Binds selectively to synaptic vesicle protein SV2A, inhibiting presynaptic neurotransmitter exocytosis.
- Kinetics: 100% oral bioavailability, low protein binding, cleared renally (requires dose adjustment for CrCl < 80 mL/min), zero CYP450 interactions.
- Safety Pearl: High incidence of neuropsychiatric adverse effects (agitation, irritability, aggression, depression, emotional lability, psychosis). Use with extreme caution in patients with underlying mood or psychotic disorders. (Brivaracetam [Briviact] has higher SV2A affinity with potentially lower psychiatric burden).
- Topiramate (Topamax: 25–200 mg BID):
- Multiple Mechanisms: Blocks voltage-gated Na+ channels, potentiates GABAA receptors, inhibits AMPA/kainate glutamate receptors, and acts as a weak carbonic anhydrase inhibitor.
- Key Adverse Effects: Weight loss / anorexia, Cognitive slowing ('Dopamax' — word-finding difficulty, impaired memory, psychomotor slowing), Nephrolithiasis / Kidney stones (carbonic anhydrase inhibition alkalinizes urine promoting calcium phosphate precipitation), Oligohidrosis / Hypohidrosis & Hyperthermia (reduced sweating, especially in hot weather/children), secondary angle-closure glaucoma, and teratogenicity (oral clefts).
- Zonisamide (Zonegran: 100–400 mg daily): Broad-spectrum agent with Na+ and T-type Ca2+ channel blockade and weak carbonic anhydrase inhibition. Strictly contraindicated in sulfonamide allergy; causes kidney stones, oligohidrosis, weight loss, and metabolic acidosis.
2. Narrow-Spectrum ASMs, Phenytoin Mathematics & Lacosamide
Carbamazepine (Tegretol: 400–1200 mg/day in divided doses)
- Therapeutic Trough Level: 4 to 12 mcg/mL.
- Auto-Induction Phenomenon: Carbamazepine is a potent substrate and inducer of CYP3A4. It induces its own metabolism; elimination half-life decreases from ~36 hours at initiation to ~12–15 hours after 2 to 4 weeks of continuous therapy. Serum levels drop unexpectedly at weeks 2–4, requiring upward dose titration.
- Mandatory Pharmacogenomic Screening (HLA-B*1502): The FDA mandates testing for the HLA-B*1502 allele in patients of Asian descent prior to initiating carbamazepine. Positive patients have a markedly elevated risk of fatal Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) (do not initiate). HLA-A*3101 screening is also recommended in European/Japanese populations.
- Adverse Effects & Monitoring: Hyponatremia / SIADH (in up to 20% of patients), boxed warning for Aplastic Anemia and Agranulocytosis, hepatotoxicity, ataxia, diplopia, osteomalacia.
- Oxcarbazepine (Trileptal): Prodrug for 10-monohydroxy derivative (MHD). Lacks auto-induction, but carries a significantly higher incidence of severe hyponatremia (SIADH) than carbamazepine (monitor serum sodium regularly). Cross-reacts in HLA-B*1502 positive patients.
Phenytoin (Dilantin): Non-Linear Michaelis-Menten Kinetics
- Therapeutic Ranges: Total Phenytoin: 10 to 20 mcg/mL; Free (Unbound) Phenytoin: 1 to 2 mcg/mL.
- Michaelis-Menten (Capacity-Limited / Zero-Order) Kinetics: Hepatic CYP2C9 and CYP2C19 enzymes become saturated within the therapeutic dosing window. At low concentrations, clearance is first-order (rate of elimination proportional to concentration). Once saturation occurs, elimination becomes zero-order (constant amount eliminated per unit time). A small, minor increase in daily dose produces a massive, disproportionate surge in serum concentration and toxicity.
Total Phenytoin Concentration vs. Daily Dose
Concentration (mcg/mL)
▲
40 ┼ / (Severe Toxicity)
│ /
30 ┼ /
│ / (Ataxia / Slurred Speech)
20 ┼ - - - - - - - - - - - - - - -/------------------ (Upper Therapeutic)
│ /
10 ┼ - - - - - - - - - - - - - / - - - - - - - - - - (Lower Therapeutic)
│ /
0 ┼────────────────────────/────────────────────────► Daily Dose (mg/day)
Saturation Point (Km)
The Sheiner-Tozer Albumin Correction Formula
Phenytoin is ~90% bound to serum albumin ($f_u = 0.1$). In the setting of hypoalbuminemia (Albumin < 4.0 g/dL) or End-Stage Renal Disease (CrCl < 20 mL/min), the free active fraction increases. Total measured phenytoin levels appear deceptively low, risking accidental overdose if misinterpreted.
- Concentration-Dependent Toxicity: Nystagmus (>20 mcg/mL), Ataxia and slurred speech (>30 mcg/mL), Lethargy, confusion, seizures, coma (>40 mcg/mL).
- Chronic Adverse Effects: Gingival hyperplasia, hirsutism, coarsening of facial features, osteomalacia / osteoporosis (induces vitamin D catabolism), peripheral neuropathy, megaloblastic anemia (folate deficiency).
Lacosamide (Vimpat: 100–200 mg BID; Schedule V Controlled Substance)
- Mechanism: Selectively enhances slow inactivation of voltage-gated sodium channels, reducing long-term channel availability without affecting physiological fast inactivation.
- Cardiac Safety Pearl: Causes dose-dependent PR interval prolongation. Obtain baseline ECG before initiation in patients with baseline cardiac conduction abnormalities (1st/2nd/3rd degree AV block, sick sinus syndrome) or concurrent PR-prolonging medications (beta-blockers, diltiazem, verapamil, digoxin).
3. Parkinson's Disease: Pathophysiology & Levodopa Optimization
Parkinson's Disease is characterized by the progressive, selective loss of dopaminergic neurons in the substantia nigra pars compacta, resulting in profound dopamine depletion in the corpus striatum and the pathological accumulation of intracellular Lewy bodies (alpha-synuclein aggregates).
Cardinal Motor Features: The TRAP Mnemonic
- T — Tremor: Resting "pill-rolling" tremor (4–6 Hz), typically unilateral at onset, suppressed during intentional purposeful movement and sleep.
- R — Rigidity: Increased resistance to passive joint movement throughout the entire range of motion ("lead-pipe" or ratchet-like "cogwheel" rigidity).
- A — Akinesia / Bradykinesia: Slowness of voluntary movement, difficulty initiating movement, masked facial expression (hypomimia), decreased spontaneous blink rate, soft monotonic speech (hypophonia), and small handwriting (micrographia).
- P — Postural Instability: Impaired postural reflexes leading to retropulsion, festinating gait, and recurrent unprovoked falls (late feature).
Carbidopa / Levodopa (Sinemet): The Pharmacological Gold Standard
Levodopa is the metabolic precursor of dopamine that crosses the blood-brain barrier via the Large Neutral Amino Acid (LAT-1) transporter, where central DOPA decarboxylase converts it into dopamine. Carbidopa is a peripheral DOPA decarboxylase inhibitor that does not cross the BBB, preventing peripheral conversion of levodopa to dopamine.
+---------------------------------------------------------------------------------------+
| CRITICAL CARBIDOPA / LEVODOPA DOSING & COUNSELING RULES |
+------------------------------------+--------------------------------------------------+
| Clinical Rule | Pharmacological Rationale & Implementation |
+------------------------------------+--------------------------------------------------+
| **Mandatory Peripheral Carbidopa | A minimum of **70 to 100 mg of elemental carbidopa|
| Threshold (70 to 100 mg/day)** | daily** is required to fully saturate peripheral |
| | DOPA decarboxylase. If carbidopa is <70 mg/day, |
| | peripheral dopamine surges cause severe nausea, |
| | vomiting, orthostatic hypotension, and arrhythmia|
| | *(Sinemet 25/100 TID provides 75 mg carbidopa; |
| | Sinemet 10/100 TID provides only 30 mg -> add |
| | supplemental carbidopa [Lodosyn 25 mg])*. |
+------------------------------------+--------------------------------------------------+
| **Dietary Protein Separation** | Dietary amino acids from high-protein meals |
| | compete with levodopa for LAT-1 intestinal |
| | absorption and BBB transport. Counsel patients to|
| | **take levodopa 30–60 min before meals** or shift|
| | major protein intake to evening dinner. |
+------------------------------------+--------------------------------------------------+
4. Adjunctive Parkinson's Therapies & Psychosis Management
Dopamine Receptor Agonists
Non-ergot dopamine agonists directly stimulate striatal D2 and D3 receptors, bypassing degenerating presynaptic nigrostriatal neurons. Often initiated in younger patients (<60–65 years) to delay levodopa-induced motor fluctuations.
- Agents: Pramipexole (Mirapex) (renally cleared), Ropinirole (Requip) (CYP1A2 substrate; smoking induces clearance, ciprofloxacin increases levels), Rotigotine (Neupro) (once-daily transdermal patch; contains aluminum, remove before MRI).
- High-Risk Class Adverse Effects:
- Impulse Control Disorders (ICDs): Pathological gambling, hypersexuality, compulsive shopping, and binge eating (mediated by D3 stimulation in the mesolimbic reward pathway). Screen routinely at every visit; requires dose reduction or discontinuation.
- Excessive Daytime Somnolence & "Sudden Sleep Attacks": Unprovoked, sudden onset of sleep without warning while engaged in activities of daily living (including driving motor vehicles). Warn patients explicitly.
- Orthostatic Hypotension & Hallucinations.
Anticholinergics & MAO-B Inhibitors
- Centrally Acting Anticholinergics (Trihexyphenidyl: 1–5 mg TID; Benztropine: 0.5–2 mg BID): Used exclusively to treat prominent resting tremor in younger patients (<65 years). Beers Criteria Warning: Strictly contraindicated in older adults (>65 years) due to severe confusion, memory loss, hallucinations, dry mouth, urinary retention, constipation, and blurred vision.
- MAO-B Inhibitors (Rasagiline, Selegiline, Safinamide): Irreversibly inhibit central MAO-B, preventing dopamine breakdown. Selegiline is metabolized to L-methamphetamine and L-amphetamine (causes insomnia; take morning/noon doses). Rasagiline does not form amphetamine metabolites. Co-administration with serotonergic agents carries warnings for Serotonin Syndrome.
Parkinson's Disease Psychosis (PDP) Management
Up to 50% of PD patients develop psychosis (visual hallucinations, paranoid delusions) driven by underlying disease progression and dopaminergic medications. Traditional antipsychotics (haloperidol, risperidone, olanzapine) block striatal D2 receptors, severely worsening motor rigidity and causing fatal immobility.
+---------------------------------------------------------------------------------------+
| EVIDENCE-BASED PARKINSON'S PSYCHOSIS THERAPY |
+------------------------------------+--------------------------------------------------+
| Therapeutic Agent & Mechanism | Clinical Role & Ambulatory Nuances |
+------------------------------------+--------------------------------------------------+
| **Pimavanserin (Nuplazid)** | **FDA Approved Drug of Choice for PDP:** |
| 34 mg orally once daily | Highly selective **5-HT2A inverse agonist / |
| (Selective 5-HT2A Inverse Agonist) | antagonist** with **ZERO affinity for D2, |
| | muscarinic, or histaminergic receptors**. |
| | Treats hallucinations without worsening motor |
| | function. (Boxed warning for elderly mortality; |
| | causes mild QTc prolongation; CYP3A4 substrate). |
+------------------------------------+--------------------------------------------------+
| **Quetiapine (Seroquel)** | Preferred off-label alternative; weak D2 affinity|
| 12.5 to 50 mg at bedtime | with rapid dissociation; minimal motor worsening.|
+------------------------------------+--------------------------------------------------+
| **Clozapine (Clozaril)** | Highly effective off-label alternative; zero |
| 6.25 to 50 mg at bedtime | motor impairment; requires strict REMS ANC TDM. |
+------------------------------------+--------------------------------------------------+
A 55-year-old female with focal epilepsy is admitted following a seizure. She has a history of severe chronic malnutrition and liver cirrhosis. Laboratory evaluation reveals a measured total serum phenytoin concentration of 8 mcg/mL (reference range: 10–20 mcg/mL) and a serum albumin concentration of 2.0 g/dL. Her renal function is normal (eGFR 95 mL/min/1.73m²). The resident physician suggests increasing her daily phenytoin dose because the total concentration is below the therapeutic range. Applying the Sheiner-Tozer correction formula, what is this patient's corrected phenytoin concentration, and what is the most appropriate clinical recommendation?
A 68-year-old male with Parkinson's disease has been successfully managed on carbidopa/levodopa 25/100 mg orally three times daily (at 07:00, 12:00, and 17:00) for the past 3 years. Over the last 4 months, he reports that his tremor, stiffness, and slow walking predictably return around 11:00 and 16:00 (approximately 1 hour before his scheduled doses). He has no involuntary twitching or dyskinesias. Which of the following therapeutic interventions is most appropriate to resolve this patient's motor symptoms?
A 32-year-old female of Han Chinese descent presents to the neurology clinic for the medical management of newly diagnosed focal impaired awareness seizures. The neurologist intends to initiate carbamazepine 200 mg twice daily. Which of the following pharmacogenomic screening tests is strictly mandatory prior to initiating carbamazepine in this patient?